Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: Proof of principle in human volunteers

Blood

Volumn 122, Issue 3, 2013, Pages 313-320

  Ghevaert, Cedric ^a,b   Herbert, Nina ^a   Hawkins, Louise ^a   Grehan, Nicola ^a   Cookson, Philip ^a   Garner, Steve F ^a,b   Crisp Hihn, Abigail ^b   Lloyd Evans, Paul ^a   Evans, Amanda ^b   Balan, Kottekkattu ^c   Ouwehand, Willem H ^a,b   Armour, Kathryn L ^d   Clark, Mike R ^d   Williamson, Lorna M ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B2G1 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G1; PROTECTIVE AGENT; RECOMBINANT ANTIBODY; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; 1A ALLOANTIGEN, HUMAN; ANTIBODY; IMMUNOGLOBULIN G; MUTANT PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; CELL PROTECTION; CHEMOLUMINESCENCE; DRUG BINDING SITE; DRUG CLEARANCE; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGLOBULIN CONSTANT REGION; IMMUNOTHERAPY; IN VIVO STUDY; MALE; MONOCYTE; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE LIFESPAN; BLOOD; BLOOD VESSEL; CELL SURVIVAL; CLINICAL TRIAL; COMPUTER PROGRAM; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; THROMBOCYTE;

ANTIBODIES; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; BLOOD VESSELS; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; MUTANT PROTEINS; RECOMBINANT PROTEINS; SOFTWARE; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84884613969     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-481887     Document Type: Article

References (42)

1. Hohlfeld P, Forestier F, Kaplan C, Tissot JD, Daffos F. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood. 1994;84(6):1851-1856. (Pubitemid 24286135)
2. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337(1): 22-26. (Pubitemid 27290843)
3. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92(7):2280-2287. (Pubitemid 28452968)
4. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839. (Pubitemid 47267418)
5. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1(8634): 363-366. (Pubitemid 19103082)
6. Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol. 2000;110(3): 735-742.
7. Davoren A, Curtis BR, Aster RH, McFarland JG. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion. 2004;44(8): 1220-1225. (Pubitemid 38989755)
8. Ghevaert C, Campbell K, Walton J, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion. 2007;47(5):901-910. (Pubitemid 46669006)
9. Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG. 2010;117(11):1335-1343.
10. Bussel JB, Zacharoulis S, Kramer K, McFarland JG, Pauliny J, Kaplan C. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer. 2005;45(2):176-183. (Pubitemid 40993584)
11. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G; Immune Thrombocytopenia Working Group. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood. 1997;89(12): 4402-4406. (Pubitemid 27260250)
12. Allen D, Verjee S, Rees S, Murphy MF, Roberts DJ. Platelet transfusion in neonatal alloimmune thrombocytopenia. Blood. 2007;109(1):388-389. (Pubitemid 46053085)
13. Allen DL, Samol J, Benjamin S, Verjee S, Tusold A, Murphy MF. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med. 2004;14(6): 409-417. (Pubitemid 39627215)
14. Bussel JB, Berkowitz RL, Lynch L, et al. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: a randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol. 1996;174(5):1414-1423. (Pubitemid 26165254)
15. van den Akker ES, Oepkes D, Lopriore E, Brand A, Kanhai HH. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG. 2007;114(4):469-473. (Pubitemid 46393288)
16. Bussel JB, Berkowitz RL, Hung C, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010;203(2): 135.e1-135.e14.
17. Vinograd CA, Bussel JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica. 2010;95(11): 1807-1811.
18. Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn. 2011;31(7):712-719.
19. Giers G, Wenzel F, Riethmacher R, Lorenz H, Tutschek B. Repeated intrauterine IgG infusions in foetal alloimmune thrombocytopenia do not increase foetal platelet counts. Vox Sang. 2010; 99(4):348-353.
20. Giers G, Wenzel F, Stockschläder M, Riethmacher R, Lorenz H, Tutschek B. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion. Haematologica. 2010;95(11):1921-1926.
21. Overton TG, Duncan KR, Jolly M, Letsky E, Fisk NM. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol. 2002;186(4):826-831. (Pubitemid 34494371)
22. Berkowitz RL, Lesser ML, McFarland JG, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Pt 1):249-255. (Pubitemid 47356647)
23. Birchall JE, Murphy MF, Kaplan C, Kroll H; European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol. 2003;122(2):275-288. (Pubitemid 36859615)
24. Goldberger A, Kolodziej M, Poncz M, Bennett JS, Newman PJ. Effect of single amino acid substitutions on the formation of the PlA and Bak alloantigenic epitopes. Blood. 1991;78(3): 681-687.
25. Griffin HM, Ouwehand WH. A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. Blood. 1995;86(12): 4430-4436.
26. Garner SF, Smethurst PA, Merieux Y, et al. A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti- HPA-1a. Br J Haematol. 2000;108(2):440-447. (Pubitemid 30143665)
27. Ghevaert C, Wilcox DA, Fang J, et al. Developing recombinant HPA-1a-specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest. 2008;118(8): 2929-2938.
28. Joutsi-Korhonen L, Preston S, Smethurst PA, et al. The effect of recombinant IgG antibodies against the leucine-33 form of the platelet beta3 integrin (HPA-1a) on platelet function. Thromb Haemost. 2004;91(4):743-754. (Pubitemid 38477455)
29. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29(8): 2613-2624. (Pubitemid 29378132)
30. MHRA. Rules and Guidance for Pharmaceutical Manufacturers and Distributors. London, UK: Pharmaceutical Press; 2007.
31. European Union. Production and quality control of monoclonal antibodies. In: The Rules Governing Medicinal Products in the European Union: Guidelines: Medicinal Products for Human Use. Vol 3. Commission of the European Communities: Luxembourg; 1994:237-262.
32. The Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Platelet radiolabeling procedure. Transfusion. 2006;46(suppl s3): 59S-66S.
33. Lötter MG, Heyns AD, Badenhorst PN, et al. Evaluation of mathematic models to assess platelet kinetics. J Nucl Med. 1986;27(7): 1192-1201.
34. Dumont LJ. Analysis and reporting of platelet kinetic studies. Transfusion. 2006;46(suppl s3): 67S-73S. (Pubitemid 44656911)
35. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol. 2003;40(9):585-593. (Pubitemid 37329917)
36. Armour KL, Parry-Jones DR, Beharry N, et al. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood. 2006;107(7): 2619-2626.
37. Chen P, Li C, Lang S, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010;116(18):3660-3668.
38. Coder PS, Thomas JA, Stedman DB, Bowman CJ. Placental transfer of 125Iodinated humanized immunoglobulin G2Da in the Sprague Dawley rat. Reprod Toxicol. 2013;38C:37-46.
39. Bertrand G, Drame M, Martageix C, Kaplan C. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood. 2011;117(11):3209-3213.
40. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica. 2008;93(6):870-877. (Pubitemid 351821723)
41. Killie MK, Husebekk A, Kaplan C, Taaning E, Skogen B. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion. 2007;47(1):55-58. (Pubitemid 46006309)
42. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion. 2012;52(7): 1446-1457.